Volume | 41,733 |
|
|||||
News | - | ||||||
Day High | 2.795 | Low High |
|||||
Day Low | 2.63 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Protara Therapeutics Inc | TARA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.71 | 2.63 | 2.795 | 2.75 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
461 | 41,733 | $ 2.70 | $ 112,548 | - | 1.04 - 5.24 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
10:02:08 | 3 | $ 2.71 | USD |
Protara Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
9.6M | 11.43M | - | 0 | -40.42M | -3.54 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Protara Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TARA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.07 | 3.15 | 2.63 | 2.82 | 166,973 | -0.38 | -12.38% |
1 Month | 3.96 | 5.24 | 2.63 | 3.56 | 577,862 | -1.27 | -32.07% |
3 Months | 2.43 | 5.24 | 2.42 | 3.60 | 249,685 | 0.26 | 10.70% |
6 Months | 1.57 | 5.24 | 1.04 | 3.19 | 146,321 | 1.12 | 71.34% |
1 Year | 3.04 | 5.24 | 1.04 | 3.10 | 86,947 | -0.35 | -11.51% |
3 Years | 15.62 | 15.95 | 1.04 | 5.80 | 89,374 | -12.93 | -82.78% |
5 Years | 25.20 | 67.079 | 1.04 | 9.23 | 80,063 | -22.51 | -89.33% |
Protara Therapeutics Description
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD). |